



GENFIT at Midcap Events in Paris, on the 17th and 18th September, 2007

Lille (France), Cambridge (Massachusetts, USA), on September 11th, 2007 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company devoted to drug discovery and development in the fields of cardiovascular, inflammatory and metabolic diseases, announces today its participation at Midcap Events on the 17th and 18th September, 2007. This event will take place in Paris, at the 'Palais Brongniart'.

Invited by Arkeon Finance, the company will be represented by Mr. Jean-François Mouney, CEO and Mr. Guillaume Lohr, Vice-President, Strategic Development.

The news of Genfit are the stock of Genfit now being continuously traded on Alternext through public offer since August 6th, 2007. Genfit's stock is from now on not any more reserved for qualified investors (Alternext: ALGFT; ISIN: FR0004163111).

In addition, GENFIT has recently reinforced its intellectual property portfolio with four new European and US patents covering its proprietary drug candidates. These new patents bring Company's total number of patents to 201.

This 7th edition of Midcap Events gathers during two days institutional investors and managers of over 150 midcap companies listed on Euronext in France, the Benelux countries and Portugal.

About GENFIT

An emerging biopharmaceutical company, GENFIT studies the deregulation of genes implicated in the most widespread diseases. GENFIT's scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT's programs, conducted in partnership with industrial pharmaceutical companies such as SANOFI-AVENTIS, PIERRE FABRE, FOURNIER (SOLVAY Group), MERCK AG, SERVIER, deal with the most prevalent metabolic and inflammatory diseases. GENFIT's internal drug discovery and development focuses on global cardiometabolic risks, attacking several pathologies (atherosclerosis, diabetes, obesity, etc.) simultaneously, using a multimodal approach to identify single molecules addressing multiples indications.

GENFIT possesses a rich and diversified pipeline of drug candidates in all stages of development, carried out by GENFIT alone or in partnership. Four molecules are in Phase II: 2 proprietary products and 2 molecules in partnership with Sanofi-Aventis (AVE8134 and AVE0847). In addition, another molecule in partnership with Sanofi-Aventis (AVE0897) is completing Phase I.

With facilities in Lille, France, and Cambridge (USA), the Company was founded by Jean-François MOUNEY, Chairman of the Management Board, with the scientific support of Jean-Charles FRUCHART, Chairman of the Supervisory Board. As of September of 2007, its staff was comprised of 130 employees, including more than 100 scientists. Genfit is a public company listed on the Alternext of EuronextTM Paris. (www.genfit.com).

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board
+ 33 (0)3 20 16 40 00

Milestones – Press Relations

Bruno Arabian
+ 33 (0)1 70 08 04 13/+ 33 (0)6 87 88 47 26
milestones@milestones-fr.com

Warning: This press release expressly contains, in an implicit manner, certain prospective statements concerning GENFIT and its activity. These statements rely on certain risks, known or unknown, uncertainty or on other factors that may lead to actual results, financial conditions, performance or achievements on the part of GENFIT that may differ significantly from the results, financial conditions, performance or achievements expressed or implied in these prospective statements. GENFIT is issuing this press release on the present date and is not committed to update the prospective statements contained therein, either as a result of new information, future events or other. For a description of the risks or uncertainty of a nature to cause a difference between GENFIT's actual results, financial conditions, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" on the Prospectus available on the GENFIT website: <http://www.genfit.com>